SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT04128878

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

This is a prospective, observational study that will examine endothelial dysfunction in atrial fibrillation before and after treatment with anti-arrhythmic agents and the extent to which baseline endothelial dysfunction improves after treatment.

NCT04128878 Atrial Fibrillation
MeSH:Atrial Fibrillation
HPO:Atrial fibrillation Paroxysmal atrial fibrillation

2 Interventions

Name: Sotalol

Description: The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
Type: Drug
Group Labels: 1

Atrial Fibrillation Cohort

Name: Dofetilide

Description: Same as described above with sotalol.
Type: Drug
Group Labels: 1

Atrial Fibrillation Cohort


Primary Outcomes

Description: Change in microvascular endothelium dependent dilation (in response to acetylcholine) assessed with laser speckle contrast imaging after initiating antiarrhythmic medical therapy.

Measure: Change in microvascular endothelium dependent dilation following anti-arrhythmic therapy as measured in perfusion units

Time: 1 year

Secondary Outcomes

Measure: Correlation between microvascular endothelial dysfunction measured at baseline and atrial fibrillation recurrence.

Time: 1 year

Measure: Correlation between microvascular endothelial function improvement with antiarrhythmic medications and atrial fibrillation recurrence.

Time: 1 year

Measure: Correlation between microvascular endothelial function and atrial fibrillation severity represented by left atrial size and type of Afib (paroxysmal vs persistent).

Time: 1 year

Measure: Change in other vasodilation dysfunction indices measured after initiating antiarrhythmic medical therapy.

Time: 1 year

Measure: Correlation between vasodilation dysfunction indices measured at baseline and atrial fibrillation recurrence.

Time: 1 year

Measure: Whether missense mutation in Cyb5R3 T117S can predict atrial fibrillation recurrence.

Time: 1 year

Measure: Whether missense mutation in Cyb5R3 T117S is correlated with atrial fibrillation severity.

Time: 1 year

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 T117S

Whether missense mutation in Cyb5R3 T117S can predict atrial fibrillation recurrence.. null. --- T117S ---

Whether missense mutation in Cyb5R3 T117S is correlated with atrial fibrillation severity.. null. --- T117S ---



HPO Nodes


HPO: